On Monday evening, the Food and Drug Administration found a way to dampen controversy over a $375,000 medicine. The agency approved a drug from Jacobus Pharmaceuticals, a small, family-run company, for treating a rare disease called Lambert-Eaton myasthenic syndrome, or LEMS, for children ages 6 to 17. The move potentially adds unforeseen competition for Catalyst Pharmaceuticals (CPRX), which only last December won an FDA endorsement to market its own treatment for adults.

The FDA approval of the Catalyst drug caused a stink. Until then, a few hundred LEMS patients were able for years to obtain the Jacobus drug for free under a compassionate use program sanctioned by the FDA. But with its approval, Catalyst obtained seven years of market exclusivity, which meant Jacobus and compound pharmacies could no longer market their versions. And while Catalyst runs patient assistance programs to offset the cost of its drug, taxpayers and insurers are footing the bill.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy